Related Experiment Video
Updated: Jul 2, 2025
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
31.9K
Bronchiectasis and asthma: Data from the European Bronchiectasis Registry (EMBARC).
Eva Polverino1, Katerina Dimakou2, Letizia Traversi1
1Pneumology Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Institut de Recerca, CIBERES, Barcelona, Spain.
The Journal of Allergy and Clinical Immunology
|February 24, 2024
Summary
Asthma is common in bronchiectasis patients, increasing exacerbation risk. Inhaled corticosteroid (ICS) use in bronchiectasis with asthma (BE+A) patients reduced mortality and hospitalizations, with unexpectedly lower overall mortality observed.
Area of Science:
- Respiratory Medicine
- Clinical Epidemiology
Background:
- Asthma is frequently diagnosed in individuals with bronchiectasis.
- Understanding the distinct clinical characteristics and outcomes of bronchiectasis with asthma (BE+A) is crucial for patient management.
Purpose of the Study:
- To compare the clinical phenotype and outcomes of patients with bronchiectasis and asthma (BE+A) against those with bronchiectasis alone.
- To investigate the impact of inhaled corticosteroid (ICS) use on outcomes in the BE+A cohort.
Main Methods:
- A prospective, pan-European observational registry (European Multicentre Bronchiectasis Audit and Research Collaboration) included 16,963 adult patients with CT-confirmed bronchiectasis.
- Asthma diagnosis was investigator-reported. Statistical analyses included negative binomial regression for exacerbation frequency and Cox proportional hazards regression for survival.
Main Results:
- 31.0% of patients had BE+A. The BE+A group was younger, more often female, never-smokers, and had higher BMI, rhinosinusitis, nasal polyps, eosinophilia, and Aspergillus sensitization.
- BE+A patients had similar microbiology but lower disease severity. They faced increased exacerbation risk but showed reduced mortality and hospitalization with ICS use.
- Unexpectedly, BE+A was associated with significantly lower all-cause mortality.
Conclusions:
- Bronchiectasis with asthma (BE+A) is prevalent and linked to higher exacerbation rates.
- Inhaled corticosteroid (ICS) therapy demonstrated a protective effect, reducing mortality and hospitalizations in BE+A patients.
- The finding of lower mortality in BE+A patients warrants further investigation.
Related Concept Videos
01:29Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
01:24Asthma-III: Symptoms and Complications
2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.5K
01:26Asthma-II: Pathophysiology and Classification
2.7K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
01:26COPD: Management Using Bronchodilators and Corticosteroids
206
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
206
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:20Asthma: Pathogenesis and Management
398
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
398